In a longitudinal in vivo study, we studied the effect of two differen
t doses of 17 beta-estradiol (E2) administered in the form of a subcut
aneous implant, on bone mineral density (BMD) of the lumbar vertebrae
(L4, L5, L4-L6/L5-L7), the calcaneus (GAL) and the distal radius (DR)
in ovariectomized (OVX) ewes. The BMD of various regions of the femur,
tibia and humerus were studied at autopsy. Skeletally mature ewes (n
= 45) were divided into four groups: sham operated (n = 12), OVX (n =
15), OVX plus one E2 implant (OVXE, n = 12) and OVX plus two E2 implan
ts (OVX2E, n = 6). BMD of L4, L5, L4-L6/L5-L7, CAL and DR was determin
ed at 0, 6 and 12 months using dual-energy X-ray absorptiomeuy. In-viv
o precision of BMD for the last three lumbar vertebrae ranged from 1.4
-4.3%, and 1.5% and 3.5% for CAL and DR respectively. In the in vivo s
tudy, there were no significant changes in the mean BMD in the sham gr
oup at any time point (each group served as its own control). In the O
VX group, mean BMD was significantly lower at L5 and DR at 6 months an
d significantly lower at L4 at 12 months. In the OVXE group, the mean
BMD was significantly higher at L5, CAL and DR at 12 months. In the OV
X2E group, BMD was significantly higher at CAL but significantly lower
at L4 at 12 months. None of the treatments produced significant chang
es of mean BMD of L4-L6/L5-L7 at any time point. Treatment influenced
the rate of change in BMD for L4 and L5 (P = 0.038, 0.041 respectively
) but not at other locations between 0 and 12 mo (repeated measures AN
OVA). The sham and OVXE groups lost less bone than the OVX and the OVX
2E groups (each group served as its own control). After 12 months, ex-
vivo measurement of BMD of the proximal and distal femur, proximal tib
ia and proximal humerus without soft tissues, showed no significant di
fference between the four treatment groups. The slight decrease in bon
e mass in the ewe following OVX was expected but we were surprised to
see a decrease in BMD of similar magnitude in IA but increases in BMD
of L5, CAL and DR in those animals with two E2 implants with time. We
suspect that a continuous supraphysiological dose of E2 may have desen
sitized the bone by downregulating estrogen receptors. L4, L5 are crit
ical sites where BMD can be measured to evaluate therapies if this mod
el is used. The CAL and DR have not been as promising.